Ponatinib (AP24534) is a novel multi-targeted kinase inhibitor that potently inhibits native and mutant BCR-ABL at clinically achievable drug levels. Ponatinib also has in vitro inhibitory activity against a discrete set of kinases implicated in the pathogenesis of other hematologic malignancies, including FLT3, KIT, FGFR1 and PDGFRα. Here, using leukemic cell lines containing activated forms of each of these receptors, we show that ponatinib potently inhibits receptor phosphorylation and cellular proliferation with 
Introduction
Ponatinib (AP24534) is an oral multi-targeted tyrosine kinase inhibitor (TKI) that has been characterized previously for its ability to potently inhibit BCR-ABL (1-3).
Importantly, ponatinib inhibits both native and mutant forms of BCR-ABL, including the T315I gatekeeper mutant that is refractory to all approved TKIs. Ponatinib is currently being investigated in a pivotal phase 2 clinical trial in patients with chronic myeloid leukemia (CML, NCT01207440, www.clinicaltrials.gov). We have previously demonstrated that ponatinib exhibits potent in vitro inhibitory activity against a discrete subset of additional protein tyrosine kinases including members of the class III/IV subfamily of receptor tyrosine kinases (RTKs) FLT3, KIT, FGFR1 and PDGFRα (2) .
Dysregulation of these RTKs, for example via genetic alterations that lead to the generation of fusion proteins or activating mutations, has been implicated in the pathogenesis of multiple hematologic malignancies (4, 5) .
Translocations affecting the activity of FGFR1 and PDGFRα are found in a subset of rare myeloproliferative neoplasms (MPNs; ref. 6) . Translocations involving the FGFR1 gene and a range of other chromosome partners such as the FGFR1OP2 gene are characteristic of 8p11 myeloproliferative syndrome (EMS), which is an aggressive disease that can rapidly transform to acute myeloid leukemia (AML; ref. 7) . The FIP1L1-PDGFRα fusion protein is found in approximately 10-20% of patients with chronic eosinophilic leukemia/idiopathic hypereosinophilia (CEL/HEL) and it has been reported that these patients respond well to PDGFR inhibition (6) . Activating mutations in KIT and FLT3 are found in AML. KIT mutations are less common and are found in specific cytogenetic subsets of AML with an overall frequency of 2-8% (8) . Activating mutations in FLT3 4 are the most common type of genetic alteration in AML, found in up to 30% of newly diagnosed patients (9) . The majority of these mutations arise from an internal tandem duplication (ITD) in the juxtamembrane region of the receptor. Activating point mutations in the kinase activation loop also occur, but with lower frequency. FLT3-ITD mutations have been associated with a worse prognosis for AML patients, both in terms of relapse and overall survival, when treated with standard therapy (9) (10) (11) .
AML is the most common myeloid disorder in adults, has the worst prognosis of all leukemias and lacks effective targeted therapies (12) . FLT3-ITD has emerged as an attractive therapeutic target, and consequently a number of small molecule TKIs with activity against FLT3 have now been developed. Many of these compounds have already been evaluated in clinical trials, including CEP-701 (lestaurtinib), PKC412 (midostaurin), sunitinib, sorafenib, MLN-518 (tandutinib) and KW-2449 (13, 14) . Overall, however, most of these agents have demonstrated relatively modest clinical activity and the effects have not been durable, suggesting that first-generation FLT3 inhibitors may have limited utility as single agents (13) (14) (15) . However, FLT3-ITD remains an attractive drug target and new inhibitors such as AC220 (16, 17) have begun to show promising clinical activity.
We evaluated the cellular activity of ponatinib against FLT3, KIT, FGFR1 and PDGFRα in a panel of leukemic cell lines that express these dysregulated RTKs in order to explore potential applications of ponatinib in hematologic malignancies beyond BCR-ABLdriven CML. We further assessed the potency and selectivity of ponatinib for FLT3-ITD 5 in primary leukemic blasts and the efficacy of ponatinib in a FLT3-ITD-driven xenograft model. phospho-STAT5 from BD Biosciences (San Jose CA). Ponatinib was synthesized at ARIAD Pharmaceuticals (Cambridge, MA) and sorafenib and sunitinib were purchased from American Custom Chemical Corporation (San Diego, CA). Stock solutions (10 mM) in DMSO of the above compounds were prepared and used in all in vitro studies. 
Cell viability assays

Immunoblot analysis
To examine inhibition of receptor tyrosine kinase signaling, cells were treated with ponatinib over a range of concentrations for 1 hour. Cells were lysed in ice-cold SDS lysis buffer (0.06 M Tris-HCL. 1% SDS and 10% glycerol) and protein concentration was determined using a BCA Protein assay (Thermo Scientific, Rockford, IL). Cellular lysates (50 µg) were resolved by electrophoresis and transferred to nitrocellulose membranes using NuPage Novex reagents (Invitrogen, Carlsbad, CA). Membranes were immunoblotted with phosphorylated antibodies and then exposed to Supersignal ELISA femto maximum sensitivity substrate (Thermo Scientific) to generate a chemiluminescent signal. Band intensity was quantified using Quantity One 4. in the Wallac Victor microplate reader. To measure PARP cleavage, MV4-11 cells were plated in 6-well plates and, the following day, were treated for 24 hours with ponatinib.
At the end of treatment cells were lysed with SDS buffer and immunoblotted to measure for both total PARP and cleaved PARP expression (Cell Signaling Technology). 
Subcutaneous xenograft model
Results
Ponatinib inhibits signaling and proliferation in hematopoietic cell lines driven by mutant, constitutively active FLT3, KIT, FGFR1 and PDGFRα
Previous studies have demonstrated that ponatinib (Fig. 1A) values between 0.3 -20 nM ( Fig. 2A and Table 1 ). Consistent with these activated receptors being important in driving leukemogenesis (4) ponatinib also potently inhibited the viability of all 4 cell lines with IC 50 values of 0.5 -17 nM ( Fig. 2B and Table 1 ). In contrast, the IC 50 for inhibition of RS4;11 cells, which express native (unmutated) FLT3, (22) was >100 nM. These data suggest that ponatinib selectively targets leukemic cells that express one of these aberrant RTKs.
The potency and activity profile of ponatinib was next compared to that of two other multi-targeted kinase inhibitors, sorafenib ( high potency against KIT (59 and 56 nM) or FGFR1 (>100 and >100 nM) ( Fig. 2B and Table 1 ).
Potent apoptotic effects of ponatinib on MV4-11 cells
Given the major clinical relevance of the FLT3-ITD mutation in AML, subsequent studies focused on the characterization of ponatinib's activity against this target. To examine the basis for ponatinib's effect on viability of FLT3-ITD-driven MV4-11 cells, its effect on 2 markers of apoptosis was measured. A dose-and time-dependent increase in caspase 3/7 activity was observed, with maximal induction (up to 4-fold) seen with 10 -30 nM ponatinib and within 16 hours of treatment (Fig. 3A) . Similarly, at concentrations ≥10 nM, ponatinib showed near maximal induction of PARP cleavage and concomitant inhibition of phosphorylation of STAT5 (Fig. 3B) , a direct downstream substrate of the mutant FLT3-ITD kinase (23) and important regulator of cell survival.
Taken together, these data suggest that inhibition of FLT3-ITD by ponatinib inhibits MV4-11 cell viability through the induction of apoptosis.
In vivo efficacy and pharmacodynamic studies
To examine the effect of ponatinib on FLT3-ITD-driven tumor growth in vivo, ponatinib (1 -25 mg/kg), or vehicle, was administered orally, once daily for 28 days, to mice bearing MV4-11 xenografts. As shown in Figure 4A 
complete and durable tumor regression with no palpable tumors detected during a 31-day follow up.
To confirm target modulation in vivo, mice bearing MV4-11 xenografts were administered a single oral dose of vehicle or ponatinib at 1, 2.5, 5 or 10 mg/kg. Tumors were harvested after 6 hours and levels of total and phosphorylated FLT3 and STAT5
were evaluated by immunoblot analysis (Fig. 4B) . A single dose of 1 mg/kg ponatinib had a modest inhibitory effect on FLT3 signaling, decreasing levels of p-FLT3 and p-STAT5 by approximately 30% (Fig. 4C) . (Fig. 4C) . These data show that inhibition of signaling by ponatinib is associated with the degree of efficacy (Fig. 4A ) and strongly suggest that inhibition of FLT3-ITD signaling accounts for the anti-tumor activity of ponatinib in this model.
Activity of ponatinib in primary AML cells
To assess the activity of ponatinib in primary cells from patients with AML, we obtained peripheral blood blasts from four patients; three that expressed native FLT3 and one that harbored a FLT3-ITD. FLT3 status was confirmed by PCR on genomic DNA from each patient (data not shown). Cell viability was measured following exposure to ponatinib for 72 hours ( However we found that ponatinib was unique in its ability to inhibit activity of all four kinases with high potency. Importantly, preliminary results reported from an ongoing phase 1 clinical trial of ponatinib that includes patients with refractory CML demonstrate that levels of ponatinib required to functionally inhibit BCR-ABL, and mutant variants, are attainable (24). In the models tested here, ponatinib exhibited potency against FLT3, KIT, FGFR1 and PDGFRα comparable to that observed previously in BCR-ABL-driven models of CML (2), suggesting that inhibition of these additional targets is clinically achievable. Overall these results provide support for clinical testing of ponatinib in diseases in which these kinases play a role. MPNs with genetic rearrangements of FGFR1 and PDGFRα are considered to be rare;
however, it has been demonstrated that the resulting fusion proteins play a major role in the pathogenesis of these diseases (6, 7) . EMS is an aggressive disease that can rapidly transform to AML in the absence of treatment. We have shown here that ponatinib potently inhibits viability of the AML KG1 cell line, which is driven by an FGFR1OP2- Multiple compounds with FLT3 activity have been described and several have already been evaluated in patients. Relatively modest clinical activity has been reported to date (11, 13, 14) , although AC220 has begun to show promise (16) . Based on preclinical studies that show that FLT3 inhibition needs to be sustained in order to effect killing of FLT3-dependent AML cells, (26) a view has emerged that in order to achieve maximum therapeutic benefit, continuous and near-complete inhibition of FLT3 kinase may be required (26) . Our in vitro studies demonstrate that complete inhibition of FLT3 
phosphorylation and function can be obtained at ≤10 nM concentrations. Importantly, preliminary analysis of the pharmacokinetic and pharmacodynamic properties of ponatinib show that well-tolerated oral daily doses lead to trough plasma drug levels exceeding 40 nM, and sustained inhibition of BCR-ABL activity in circulating leukemic cells (24). These data suggest that the potency and pharmacologic properties of ponatinib may allow continuous and near-complete inhibition of FLT3 in patients.
In summary, ponatinib is a multi-targeted kinase inhibitor that displays potent inhibition of FLT3 and is cytotoxic to AML cells harboring the FLT3-ITD mutation. Importantly, this agent exhibits activity against additional RTKs, FGFR1, KIT and PDGFRα, which have also been shown to play roles in the pathogenesis of hematologic malignancies.
Notably, the potency of ponatinib against these RTKs in vitro and plasma levels of ponatinib observed in humans suggest that ponatinib may have clinical activity against these targets. Taken together, these observations provide strong preclinical support for the evaluation of ponatinib as a novel therapy for AML and other hematologic malignancies. 
